Table 2.
Baseline Clinical Characteristics of the mrEF DCM Group Divided According to Evolution/No Evolution to rEF (LVEF <40%)
| No Evolution to rEF Group (n=146) | Evolution to rEF Group (n=29) | P Value | |
|---|---|---|---|
| Age, y | 42±6 | 42±15 | 0.84 |
| Male sex (%) | 91 (62%) | 19 (65%) | 0.74 |
| NYHA III–IV, n (%) | 6 (4) | 3 (10) | 0.15 |
| SBP, mm Hg | 125±16 | 129±18 | 0.17 |
| Heart rate, bpm | 69±12 | 73±12 | 0.14 |
| LBBB (%) | 29 (19%) | 6 (20%) | 0.94 |
| Echocardiography | |||
| LAESAI, cm2/m2 | 9±2 | 9±3 | 0.82 |
| LVEDDI, mm/m2 | 31±3 | 32±4 | 0.72 |
| LVEDVI, mL/m2 | 70±18 | 70±15 | 0.67 |
| LVEF, % | 44.1±2.6 | 44.3±3.0 | 0.70 |
| RVD, n (%) | 12 (8) | 5 (17) | 0.15 |
| Moderate–severe MR, n (%) | 16 (11) | 7 (24) | 0.057 |
| Restrictive LV filling pattern, n (%) | 4 (2) | 4 (14) | 0.02 |
| E/E′ | 10±3 | 11±4 | 0.11 |
| sPAP | 24±5 | 29±5 | 0.017 |
| Therapy | |||
| ACE‐inhibitors‐ARBs, n (%) | 146 (100) | 29 (100) | 0.34 |
| Beta‐blockers, n (%) | 127 (88) | 26 (88) | 0.82 |
| Diuretics, n (%) | 58 (40) | 18 (62) | 0.02 |
| MRAs, n (%) | 15 (10) | 8 (27) | 0.02 |
Values are expressed as mean±SD or median with interquartile range as appropriate, and as percentage. ACE indicates angiotensin‐converting enzyme; ARBs, angiotensin receptor blockers; LAESAI, left atrial end systolic area indexed; LBBB, left bundle branch block; LV, left ventricular; LVEDDI, left ventricular end‐diastolic diameter indexed; LVEDVI, left ventricular end‐diastolic volume indexed; LVEF, left ventricular ejection fraction; MR, mitral regurgitation; MRAs, mineralocorticoid receptor antagonists; NYHA, New York Heart Association; RVD, right ventricular dysfunction; SBP, systolic blood pressure; sPAP, systolic pulmonary artery pressure.